Abstract
Anaplastic thyroid carcinoma is the rarest but extremely aggressive thyroid cancer subtype. This neoplasia is composed of undifferentiated tumor cells with poor prognosis and resistant to common thyroid cancer therapy. Early stage identification of this cancer for prompt treatment is very vital. Presently, cytological evaluation of fine needle aspiration biopsy (FNAB) which is known as invasive recognition assay, is the standard diagnostic method for the diagnosis of malignant thyroid tumors. Frequent studies have suggested that using the molecular biomarkers of thyroid cancer tissue alongside cytological examination, increase the accuracy of diagnostic tests. Also, these agents could be beneficial for effective target therapy and personalize medicine. In this review, the molecular biomarkers that are involved in anaplastic thyroid carcinoma in four category (gene mutation profile, epigenetic profile, microRNA profile and cancer stem cell markers) were summarized.
Keywords: Anaplastic thyroid carcinoma, molecular biomarkers, gene mutation profile, epigenetic profile, microRNA profile, cancer stem cell markers.
Current Molecular Medicine
Title:Molecular Biomarkers of Anaplastic Thyroid Carcinoma
Volume: 17 Issue: 3
Author(s): F. Bozorg-Ghalati*M. Hedayati
Affiliation:
- Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran,Iran
Keywords: Anaplastic thyroid carcinoma, molecular biomarkers, gene mutation profile, epigenetic profile, microRNA profile, cancer stem cell markers.
Abstract: Anaplastic thyroid carcinoma is the rarest but extremely aggressive thyroid cancer subtype. This neoplasia is composed of undifferentiated tumor cells with poor prognosis and resistant to common thyroid cancer therapy. Early stage identification of this cancer for prompt treatment is very vital. Presently, cytological evaluation of fine needle aspiration biopsy (FNAB) which is known as invasive recognition assay, is the standard diagnostic method for the diagnosis of malignant thyroid tumors. Frequent studies have suggested that using the molecular biomarkers of thyroid cancer tissue alongside cytological examination, increase the accuracy of diagnostic tests. Also, these agents could be beneficial for effective target therapy and personalize medicine. In this review, the molecular biomarkers that are involved in anaplastic thyroid carcinoma in four category (gene mutation profile, epigenetic profile, microRNA profile and cancer stem cell markers) were summarized.
Export Options
About this article
Cite this article as:
Bozorg-Ghalati F. *, Hedayati M. , Molecular Biomarkers of Anaplastic Thyroid Carcinoma, Current Molecular Medicine 2017; 17 (3) . https://dx.doi.org/10.2174/1566524017666170822102417
DOI https://dx.doi.org/10.2174/1566524017666170822102417 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radioiodine Treatment of Differentiated Thyroid Carcinoma: The Experience at Seoul National University Hospital
Current Medical Imaging Animal Models of Xenobiotic Receptors
Current Drug Metabolism Peptides for In Vivo Target-Specific Cancer Imaging
Mini-Reviews in Medicinal Chemistry Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy
Current Medicinal Chemistry Sleep Duration as a Risk Factor for Cardiovascular Disease- a Review of the Recent Literature
Current Cardiology Reviews Ferroptosis: A Trusted Ally in Combating Drug Resistance in Cancer
Current Medicinal Chemistry Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Current Medicinal Chemistry Traversing the Skin Barrier with Nano-emulsions
Current Drug Delivery The Biological Effects of Diagnostic Cardiac Imaging
Current Pharmaceutical Design Chemokines in the Pathogenesis and as Therapeutical Markers and Targets of HCV Chronic Infection and HCV Extrahepatic Manifestations
Current Drug Targets Targeting Tumor Proteasome with Traditional Chinese Medicine
Current Drug Discovery Technologies Insulin Analogs Revisited
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Our Little Friends with Big Roles: Alterations of the Gut Microbiota in Thyroid Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Personalized Diabetes and Cancer Medicine: A Rationale for Anti-Diabetic Nutrition (Bitter Melon) in a Supportive Setting
Current Cancer Therapy Reviews The Effect of a Ferrocene Containing Camphor Sulfonamide DK-164 on Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry The Potential of Flavonoids and Tannins from Medicinal Plants as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry A Review on the Use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis
Current Drug Targets Mitochondrial Alterations and Neuropsychiatric Disorders
Current Medicinal Chemistry